Adjuvant Global Health Technology Fund, L.P. - 29 Mar 2022 Form 4/A - Amendment Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
10%+ Owner
Signature
Adjuvant Global Health Technology Fund, L.P., By: Adjuvant Capital GP, L.P., its sole general partner, By: Adjuvant Capital Management, L.L.C., its sole general partner By: Kabeer Aziz, Secretary /s/ Kabeer Aziz
Issuer symbol
ANTX
Transactions as of
29 Mar 2022
Net transactions value
+$2,499,990
Form type
4/A - Amendment
Filing time
24 Jun 2022, 16:51:56 UTC
Date Of Original Report
31 Mar 2022
Previous filing
24 Jun 2022
Next filing
24 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANTX Common Stock Conversion of derivative security +1,651,636 1,651,636 29 Mar 2022 Direct F1, F2
transaction ANTX Common Stock Conversion of derivative security +312,415 312,415 29 Mar 2022 By Adjuvant Global Health Technology Fund DE, L.P. F1, F3
transaction ANTX Common Stock Conversion of derivative security +392,433 +24% 2,044,069 29 Mar 2022 Direct F1, F2
transaction ANTX Common Stock Conversion of derivative security +74,230 +24% 386,645 29 Mar 2022 By Adjuvant Global Health Technology Fund DE, L.P. F1, F3
transaction ANTX Common Stock Purchase $2,499,990 +166,666 +8.2% $15.00 2,210,735 29 Mar 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANTX Series A Convertible Preferred Stock Conversion of derivative security $0 -1,651,636 -100% $0.000000* 0 29 Mar 2022 Common Stock 1,651,636 Direct F1, F2
transaction ANTX Series A Convertible Preferred Stock Conversion of derivative security $0 -312,415 -100% $0.000000* 0 29 Mar 2022 Common Stock 312,415 By Adjuvant Global Health Technology Fund DE, L.P. F1, F3
transaction ANTX Series B Convertible Preferred Stock Conversion of derivative security $0 -392,433 -100% $0.000000* 0 29 Mar 2022 Common Stock 392,433 Direct F1, F2
transaction ANTX Series B Convertible Preferred Stock Conversion of derivative security $0 -74,230 -100% $0.000000* 0 29 Mar 2022 Common Stock 74,230 By Adjuvant Global Health Technology Fund DE, L.P. F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date.
F2 Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
F3 Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.